Biotech Industry · us
Estuary launches with $103 million to develop gene therapies delivered directly to the kidneys for polycystic kidney disease
Mouse studies suggest that restoring expression of a key protein could improve established polycystic kidney disease. Estuary will pursue this approach with two gene therapies, but whether they can be safely delivered to human kidneys and provide lasting benefits remains to be validated in clinical trials.
Once cysts have formed in the kidneys, can replacing a key protein that cells lack still reverse the damage? This finding from mouse experiments became the starting point for Estuary Biotherapeutics’ gene therapy development. On October 16, the company announced its launch with a total of $103 million in financing, targeting autosomal dominant polycystic kidney disease (ADPKD) with the aim of bringing its protein function restoration approach into human trials.
The funding includes an earlier $10 million seed round and a newly completed $93 million Series A. According to an announcement from investor 4BIO Capital, RA Capital Management led the Series A, with 4BIO and GV continuing to participate after co-leading the seed round. The funds will support the advancement of two lead therapy candidates to obtain initial human proof-of-concept data, as well as the development of a kidney gene delivery platform.
Polycystin is at the core of the development effort. Estuary’s scientific foundation comes from research by Stefan Somlo and Michael Caplan at Yale School of Medicine: restoring polycystin expression in mouse kidneys with established cystic disease can improve kidney structure and function. A separate finding indicates that a compact functional region of polycystin-1 (PC1) alone is sufficient to suppress cystic disease. These results offer a therapeutic direction, but do not yet establish that the same effects will be reproduced in humans.
Following these two lines of research, Estuary designed EST-201 and EST-101, respectively. The former uses an adeno-associated virus (AAV) to carry the full PKD2 gene and is intended for patients with PKD2 mutations; the latter delivers a functional region derived from PC1 and is intended for patients with PKD1 mutations. Under the company’s current plans, the two therapies will enter clinical trials in 2027 and 2028, respectively. These timelines remain development targets.
Delivering the treatment to the right location is critical to this approach. Both programs use local administration to the kidneys, with the goal of enabling kidney epithelial cells to express the required proteins and restoring polycystin levels within nephrons—the kidneys’ basic functional units. According to 4BIO, this design aims to reduce the potential toxicity of systemic AAV administration. However, whether local administration can adequately reach the cells that need treatment, and how much it can reduce risk, remain questions for experimental and clinical data to answer.
For Estuary, the new funding makes the path from mouse research to human validation more concrete, but efficacy and safety have yet to be established. Even with the therapies aiming for a single administration, follow-up will be needed to determine how long protein expression lasts, whether kidney function can be preserved, and whether adverse effects emerge over the long term. The most significant development for now is that the two therapy candidates have secured resources to advance toward clinical trials; whether they can alter the course of patients’ disease remains to be answered in subsequent trials.